Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Herbal formula Huang Qin Ge Gen Tang enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway.

Liu H, Liu H, Zhou Z, Parise RA, Chu E, Schmitz JC.

Cell Commun Signal. 2018 Feb 20;16(1):7. doi: 10.1186/s12964-018-0218-1.

2.

Targeting p53-dependent stem cell loss for intestinal chemoprotection.

Leibowitz BJ, Yang L, Wei L, Buchanan ME, Rachid M, Parise RA, Beumer JH, Eiseman JL, Schoen RE, Zhang L, Yu J.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaam7610. doi: 10.1126/scitranslmed.aam7610.

PMID:
29437148
3.

Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.

Christner S, Guo J, Parise RA, Ringeval M, Hoye AT, Wipf P, Epperly MW, Greenberger JS, Beumer JH, Eiseman JL.

J Pharm Biomed Anal. 2018 Feb 20;150:169-175. doi: 10.1016/j.jpba.2017.12.023. Epub 2017 Dec 12.

PMID:
29245086
4.

LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.

Kiesel BF, Scemama J, Parise RA, Villaruz L, Iffland A, Doyle A, Ivy P, Chu E, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:244-250. doi: 10.1016/j.jpba.2017.08.037. Epub 2017 Aug 31.

PMID:
28888173
5.

LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.

Matsumoto J, Kiesel BF, Parise RA, Guo J, Taylor S, Huang M, Eiseman JL, Ivy SP, Kunos C, Chu E, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:154-160. doi: 10.1016/j.jpba.2017.08.036. Epub 2017 Aug 31.

PMID:
28881312
6.

Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.

Kim KP, Parise RA, Holleran JL, Lewis LD, Appleman L, van Erp N, Morris MJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:197-205. doi: 10.1016/j.jpba.2017.02.018. Epub 2017 Feb 13.

7.

LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma.

Kiesel BF, Shogan JC, Rachid M, Parise RA, Vendetti FP, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:158-165. doi: 10.1016/j.jpba.2017.01.055. Epub 2017 Feb 4.

8.

LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.

Kiesel BF, Parise RA, Wong A, Keyvanjah K, Jacobs S, Beumer JH.

J Pharm Biomed Anal. 2017 Feb 5;134:130-136. doi: 10.1016/j.jpba.2016.11.035. Epub 2016 Nov 22.

9.

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1225-1235. Epub 2016 Oct 24.

10.

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2016 Sep 10;129:359-366. doi: 10.1016/j.jpba.2016.07.027. Epub 2016 Jul 18.

11.

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.

Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. Epub 2016 Jan 19.

12.

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

Parise RA, Eiseman JL, Clausen DM, Kicielinski KP, Hershberger PA, Egorin MJ, Beumer JH.

Cancer Chemother Pharmacol. 2015 Sep;76(3):537-46. doi: 10.1007/s00280-015-2828-2. Epub 2015 Jul 21.

13.

Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Beumer JH, Pillai VC, Parise RA, Christner SM, Kiesel BF, Rudek MA, Venkataramanan R.

Br J Clin Pharmacol. 2015 Nov;80(5):1097-108. doi: 10.1111/bcp.12723. Epub 2015 Sep 19.

14.

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction.

Christner SM, Clausen DM, Beumer JH, Parise RA, Guo J, Huang Y, Dömling AS, Eiseman JL.

Cancer Chemother Pharmacol. 2015 Aug;76(2):287-99. doi: 10.1007/s00280-015-2791-y. Epub 2015 Jun 7.

15.

Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs.

Muzzio M, Hu SC, Holleran JL, Parise RA, Eiseman JL, Yellow-Duke AE, Covey JM, Glaze ER, Engelke K, Egorin MJ, McCormick DL, Beumer JH.

Cancer Chemother Pharmacol. 2015 May;75(5):1015-23. doi: 10.1007/s00280-015-2722-y. Epub 2015 Mar 17.

16.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

17.

Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS.

Christner SM, Parise RA, Levine ED, Rizvi NA, Gounder MM, Beumer JH.

J Pharm Biomed Anal. 2014 Nov;100:199-204. doi: 10.1016/j.jpba.2014.08.007. Epub 2014 Aug 12.

18.

Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.

Pillai VC, Parise RA, Christner SM, Rudek MA, Beumer JH, Venkataramanan R.

J Clin Pharmacol. 2014 Nov;54(11):1272-9. doi: 10.1002/jcph.333. Epub 2014 May 27.

PMID:
24846165
19.

VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells.

Solomon JD, Heitzer MD, Liu TT, Beumer JH, Parise RA, Normolle DP, Leach DA, Buchanan G, DeFranco DB.

Mol Cancer Res. 2014 Aug;12(8):1166-80. doi: 10.1158/1541-7786.MCR-13-0395. Epub 2014 May 13.

20.

Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.

Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, Smith CA, Eiseman JL.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1195-204. doi: 10.1007/s00280-013-2296-5. Epub 2013 Sep 24.

21.

Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.

Pillai VC, Venkataramanan R, Parise RA, Christner SM, Gramignoli R, Strom SC, Rudek MA, Beumer JH.

Drug Metab Dispos. 2013 Oct;41(10):1843-51. doi: 10.1124/dmd.113.052100. Epub 2013 Aug 2.

22.

LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.

Kiesel BF, Parise RA, Tjørnelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2013 Jul-Aug;81-82:89-98. doi: 10.1016/j.jpba.2013.03.025. Epub 2013 Apr 9.

23.

In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.

Guo J, Clausen DM, Beumer JH, Parise RA, Egorin MJ, Bravo-Altamirano K, Wipf P, Sharlow ER, Wang QJ, Eiseman JL.

Cancer Chemother Pharmacol. 2013 Feb;71(2):331-44. doi: 10.1007/s00280-012-2010-z. Epub 2012 Oct 30.

24.

Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

Parise RA, Anyang BN, Eiseman JL, Egorin MJ, Covey JM, Beumer JH.

Cancer Chemother Pharmacol. 2013 Jan;71(1):73-83. doi: 10.1007/s00280-012-1980-1. Epub 2012 Oct 5.

25.

A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay.

Beumer JH, Parise RA, Kanterewicz B, Petkovich M, D'Argenio DZ, Hershberger PA.

Steroids. 2012 Apr;77(5):477-83. doi: 10.1016/j.steroids.2012.01.007. Epub 2012 Jan 20.

26.

Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.

Koon HB, Fingleton B, Lee JY, Geyer JT, Cesarman E, Parise RA, Egorin MJ, Dezube BJ, Aboulafia D, Krown SE.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.

27.

In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.

Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL.

J Pharmacol Exp Ther. 2010 Dec;335(3):715-27. doi: 10.1124/jpet.110.170555. Epub 2010 Aug 26.

28.

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH.

J Liposome Res. 2011 Mar;21(1):70-80. doi: 10.3109/08982101003754385. Epub 2010 Jun 9.

PMID:
20528623
29.

Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6. Epub 2010 May 5.

30.

Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH.

J Pharm Biomed Anal. 2010 Sep 5;52(5):714-20. doi: 10.1016/j.jpba.2010.02.020. Epub 2010 Feb 23.

31.

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

Parise RA, Egorin MJ, Christner SM, Shah DD, Zhou W, Beumer JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1894-900. doi: 10.1016/j.jchromb.2009.05.034. Epub 2009 May 21.

32.

Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells.

Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, Zeng Y, Hahm ER, Marynowski SW, Bommareddy A, Desai D, Amin S, Parise RA, Beumer JH, Chambers WH.

Cancer Res. 2009 Mar 1;69(5):2117-25. doi: 10.1158/0008-5472.CAN-08-3502. Epub 2009 Feb 17.

33.

Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.

Parise RA, Shawaqfeh M, Egorin MJ, Beumer JH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 1;872(1-2):141-7. doi: 10.1016/j.jchromb.2008.07.032. Epub 2008 Jul 31.

34.

Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ.

Clin Cancer Res. 2008 Jun 1;14(11):3529-35. doi: 10.1158/1078-0432.CCR-07-4885.

35.

Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.

Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL.

Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25. doi: 10.1007/s00280-008-0774-y. Epub 2008 May 29.

36.

Effect of antacid on imatinib absorption.

Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH.

Cancer Chemother Pharmacol. 2009 Feb;63(3):525-8. doi: 10.1007/s00280-008-0778-7. Epub 2008 May 24.

37.

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.

Gibbons J, Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CH, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP, Remick SC; National Cancer Institute Organ Dysfunction Working Group.

J Clin Oncol. 2008 Feb 1;26(4):570-6. doi: 10.1200/JCO.2007.13.3819.

PMID:
18235116
38.

Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.

Parise RA, Beumer JH, Kangani CO, Holleran JL, Eiseman JL, Smith NF, Covey JM, Perrine SP, Egorin MJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):168-74. Epub 2007 Dec 8.

39.

Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.

Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL.

Clin Cancer Res. 2007 Dec 1;13(23):7217-23.

40.

Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Beumer JH, Eiseman JL, Parise RA, Florian JA Jr, Joseph E, D'Argenio DZ, Parker RS, Kay B, Covey JM, Egorin MJ.

Cancer Chemother Pharmacol. 2008 Aug;62(3):457-64. Epub 2007 Nov 15.

41.

Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284).

Guo J, Parise RA, Joseph E, Lan J, Pan SS, Joo B, Egorin MJ, Wipf P, Lazo JS, Eiseman JL.

Anticancer Res. 2007 Sep-Oct;27(5A):3067-73.

42.

Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.

Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, Eiseman JL.

Cancer Chemother Pharmacol. 2008 Aug;62(3):417-26. Epub 2007 Oct 24.

PMID:
17957368
43.

Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ.

Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. Epub 2007 Sep 26.

PMID:
17899082
44.
45.

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP.

Clin Cancer Res. 2007 Jun 15;13(12):3605-10. Epub 2007 May 17. Erratum in: Clin Cancer Res. 2007 Oct 15;13(20):6245. Ramananthan, Ramesh K [corrected to Ramanathan, Ramesh K].

46.

Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.

Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ.

Clin Cancer Res. 2006 Dec 15;12(24):7483-91. Epub 2006 Nov 30.

47.

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.

Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 18;840(2):108-15. Epub 2006 May 24.

PMID:
16725386
48.

CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer.

Parise RA, Egorin MJ, Kanterewicz B, Taimi M, Petkovich M, Lew AM, Chuang SS, Nichols M, El-Hefnawy T, Hershberger PA.

Int J Cancer. 2006 Oct 15;119(8):1819-28.

49.

Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).

Lichtman SM, Hollis D, Miller AA, Rosner GL, Rhoades CA, Lester EP, Millard F, Byrd J, Cullinan SA, Rosen DM, Parise RA, Ratain MJ, Egorin MJ; Cancer and Leukemia Group B (CALGB 9762).

J Clin Oncol. 2006 Apr 20;24(12):1846-51. Epub 2006 Mar 27.

PMID:
16567769
50.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S.

Invest New Drugs. 2006 Sep;24(5):393-401.

PMID:
16505951

Supplemental Content

Loading ...
Support Center